Juvenile Arthritis News

The American College of Rheumatology has partnered with the American Association of Hip and Knee Surgeons to develop evidence-based guidelines for perioperative management of antirheumatic medication for patients with rheumatic diseases who undergo total joint replacement.

The American College of Rheumatology has partnered with the American Association of Hip and Knee Surgeons to develop evidence-based guidelines for perioperative management of antirheumatic medication for patients with rheumatic diseases who undergo total joint replacement.

Subcutaneous abatacept is now available for patients aged 2 years or older with moderately to severely active polyarticular juvenile idiopathic arthritis, according to a company press release. The new prefilled syringe allows for the treatment to be administered at home.

The FDA has approved Xatmep, an oral methotrexate solution for the treatment of polyarticular juvenile idiopathic arthritis in children with inadequate response to NSAIDs and for children with acute lymphoblastic leukemia as part of multiphase combination chemotherapy.

Among patients with rheumatoid arthritis and patients with a polyarticular subtype of juvenile idiopathic arthritis, researchers at University College London compared profiles of antibodies to cyclic citrullinated peptide profiles.

The Committee for Medicinal Products for Human Use has recommended approval of biosimilars by Sandoz for rituximab and etanercept for the same indications as the respective reference products.

Published criteria to identify inactive disease or low disease activity do not always identify the same patients, according to a recently published study.

Patients with inflammatory arthritis who underwent total hip arthroplasty experienced higher rates of complications compared with patients who had osteoarthritis, according to results.

Investigators found a slightly increased risk for serious infection among patients with juvenile idiopathic arthritis who took first-line etanercept or adalimumab compared with patients who took methotrexate alone, according to recently published data.

The European Commission has approved Amgevita, a biosimilar to adalimumab, for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, severe active ankylosing spondylitis, severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis in addition to moderate to severe chronic plaque psoriasis, moderate-to-severe hidradenitis suppurativa, non-infectious intermediate, posterior and panuveitis, moderate to severe Crohn’s disease and moderate to severe ulcerative colitis. It is also approved for Crohn’s disease in children aged 6 years and older, severe chronic plaque psoriasis in children aged 4 years and older, enthesitis-related arthritis in children aged 6 years and older and polyarticular juvenile idiopathic arthritis in children aged 2 years and older.